Leonard C. Glass

4.1k total citations · 2 hit papers
32 papers, 3.3k citations indexed

About

Leonard C. Glass is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Leonard C. Glass has authored 32 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Leonard C. Glass's work include Diabetes Treatment and Management (16 papers), Diabetes Management and Research (15 papers) and Metabolism, Diabetes, and Cancer (14 papers). Leonard C. Glass is often cited by papers focused on Diabetes Treatment and Management (16 papers), Diabetes Management and Research (15 papers) and Metabolism, Diabetes, and Cancer (14 papers). Leonard C. Glass collaborates with scholars based in United States, Italy and Russia. Leonard C. Glass's co-authors include Ralph A. DeFronzo, Yoshinori Miyazaki, Lawrence J. Mandarino, Ralph A. DeFronzo, Michelle S. Lewis, Masafumi Matsuda, Swangjit Suraamornkul, L. Jean Hardies, Curtis Triplitt and Richard M. Bergenstal and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Leonard C. Glass

31 papers receiving 3.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

2013 730 citations Gregory Gaich, Jenny Y. Chien et al. Cell Metabolism profile →
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

2025 95 citations Leonard C. Glass et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leonard C. Glass United States	18	1.8k	1.7k	854	763	599	32	3.3k
Martin Ridderstråle Sweden	29	1.4k 0.8×	1.4k 0.8×	1.2k 1.4×	1.1k 1.4×	615 1.0×	84	3.7k
Renata Belfort United States	14	1.0k 0.6×	1.3k 0.8×	1.8k 2.1×	1.0k 1.3×	585 1.0×	16	3.1k
Bogdan Balas United States	18	1.1k 0.6×	1.6k 0.9×	1.8k 2.1×	700 0.9×	587 1.0×	36	3.6k
Luke Norton United States	26	1.6k 0.9×	2.3k 1.3×	316 0.4×	598 0.8×	1.4k 2.3×	54	3.4k
Agata Maria Rabuazzo Italy	30	911 0.5×	1.3k 0.8×	711 0.8×	595 0.8×	1.2k 2.0×	91	3.0k
Mirja Tiikkainen Finland	14	533 0.3×	1.1k 0.7×	1.1k 1.3×	555 0.7×	342 0.6×	18	2.1k
Marcel H.A. Muskiet Netherlands	28	870 0.5×	2.5k 1.5×	408 0.5×	412 0.5×	1.1k 1.9×	66	3.5k
Murray Stewart United Kingdom	31	1.2k 0.7×	2.2k 1.3×	275 0.3×	358 0.5×	975 1.6×	68	3.1k
Brenno Astiarraga Italy	20	746 0.4×	1.3k 0.7×	459 0.5×	766 1.0×	1.1k 1.9×	44	2.4k
Robert Bergholm Finland	27	770 0.4×	1.5k 0.9×	2.2k 2.6×	977 1.3×	446 0.7×	34	4.0k

Countries citing papers authored by Leonard C. Glass

Since Specialization

Citations

This map shows the geographic impact of Leonard C. Glass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard C. Glass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard C. Glass more than expected).

Fields of papers citing papers by Leonard C. Glass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard C. Glass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard C. Glass. The network helps show where Leonard C. Glass may publish in the future.

Co-authorship network of co-authors of Leonard C. Glass

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard C. Glass. A scholar is included among the top collaborators of Leonard C. Glass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard C. Glass. Leonard C. Glass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brouwers, Bram, Girish S. Rao, Yuanyuan Tang, et al.. (2024). Incretin-based investigational therapies for the treatment of MASLD/MASH. Diabetes Research and Clinical Practice. 211. 111675–111675. 18 indexed citations

Curtis, Bradley, Sarah L. Hulin-Curtis, Daniel R. Murphy, et al.. (2016). Evaluation of a patient self-directed mealtime insulin titration algorithm: a US payer perspective. Journal of Medical Economics. 19(6). 549–556. 1 indexed citations

Johnson, Jennal, et al.. (2016). A Patient-Driven Approach to Manage Mealtime Insulin Titration. The Diabetes Educator. 42(3). 271–280. 1 indexed citations

Thrasher, James, Anuj Bhargava, Tina M. Rees, et al.. (2014). Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients With Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart. Endocrine Practice. 21(3). 247–257. 4 indexed citations

Edelman, Steve, Rong Liu, Jennal Johnson, & Leonard C. Glass. (2014). AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care. 37(8). 2132–2140. 28 indexed citations

Gaich, Gregory, Jenny Y. Chien, Haoda Fu, et al.. (2013). The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metabolism. 18(3). 333–340. 730 indexed citations breakdown →

Rosenstock, Julio, Sylvia Shenouda, Richard M. Bergenstal, et al.. (2012). Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. Diabetes Care. 35(5). 955–958. 59 indexed citations

DeFronzo, Ralph A., Curtis Triplitt, Yongming Qu, et al.. (2010). Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin. Diabetes Care. 33(5). 951–957. 89 indexed citations

Glass, Leonard C., Yongming Qu, Sheila M. Lenox, et al.. (2008). Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Current Medical Research and Opinion. 24(3). 639–644. 29 indexed citations

10.

Bajaj, Mandeep, Swangjit Suraamornkul, L. Jean Hardies, et al.. (2007). Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 50(8). 1723–1731. 121 indexed citations

11.

Thomaseth, Karl, et al.. (2007). Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Computer Methods and Programs in Biomedicine. 89(2). 132–140. 16 indexed citations

12.

Berria, Rachele, Leonard C. Glass, Archana Mahankali, et al.. (2007). Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus. Clinical Pharmacology & Therapeutics. 82(3). 275–281. 70 indexed citations

13.

Triplitt, Curtis, Leonard C. Glass, Estela Wajcberg, et al.. (2006). Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea. Diabetes Care. 29(11). 2371–2377. 17 indexed citations

14.

Bajaj, Mandeep, Swangjit Suraamornkul, L. Jean Hardies, et al.. (2004). Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients. The Journal of Clinical Endocrinology & Metabolism. 89(1). 200–206. 309 indexed citations

15.

Bajaj, Mandeep, Swangjit Suraamornkul, Thongchai Pratipanawatr, et al.. (2003). Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes. Diabetes. 52(6). 1364–1370. 238 indexed citations

16.

Ferrannini, Ele, Amalia Gastaldelli, Masafumi Matsuda, et al.. (2003). Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis. The Journal of Clinical Endocrinology & Metabolism. 88(7). 3251–3257. 42 indexed citations

17.

Glass, Leonard C.. (2003). Pituitary Apoplexy. New England Journal of Medicine. 349(21). 2034–2034. 5 indexed citations

18.

Matsuda, Masafumi, Ralph A. DeFronzo, Leonard C. Glass, et al.. (2002). Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism. 51(9). 1111–1119. 70 indexed citations

19.

Matsuda, Masafumi, et al.. (2002). Effect of misoprostol (PGE1) on glucose metabolism in type‐2‐diabetic and control subjects. Diabetes Obesity and Metabolism. 4(3). 195–200. 2 indexed citations

20.

Miyazaki, Yoshinori, Archana Mahankali, Masafumi Matsuda, et al.. (2001). Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone. Diabetes Care. 24(4). 710–719. 347 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact